Cytovance Biologics
- Company typePrivate
- Founded2005
- HeadquartersOklahoma City, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
Cytovance Biologics firmographics
Firmographics- Name
- Cytovance Biologics
- Legal name
- Cytovance Biologics, Inc.
- Website
- https://cytovance.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Cytovance Biologics industry classification
Industry- Product category
- Biologics Contract Manufacturing (CDMO)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where Cytovance Biologics is headquartered
LocationHeadquarters
- HQ city
- Oklahoma City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cytovance Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure
Revenue model
- cGMP Contract Manufacturing (Clinical & Commercial): Cytovance's primary revenue stream is fee-for-service contract development and manufacturing (CDMO) for biologics, covering both mammalian cell culture and microbial fermentation from preclinical through commercial phases. Revenue is generated on a project-by-project basis, with flexible pricing structures accommodating clients across the spectrum from small biotech to large pharma. The company has supported three commercially approved drug products and 300+ client programs globally.
- Process Development and Analytical Services: Cytovance generates revenue from integrated process development, cell line development, strain development, analytical method development, process characterization, and regulatory support services. These are offered as part of the end-to-end CDMO service continuum, bundled with manufacturing or as standalone engagements.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Cytovance Biologics product offering
Product offeringCore offering
Cytovance Biologics is a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) that develops and manufactures large-molecule therapeutics—including monoclonal antibodies, fusion proteins, enzymes, vaccines, and recombinant proteins—from both mammalian cell culture (CHO) and microbial fermentation (E. coli and yeast). The company offers end-to-end services spanning strain and cell line development, upstream and downstream process development, analytical development, cGMP manufacturing (up to 2,000L single-use bioreactors and 1,000L microbial fermenters), fill-finish, regulatory support, and global logistics.
Product overview
Cytovance Biologics is a fully integrated biologics CDMO (Contract Development and Manufacturing Organization) offering comprehensive large molecule development and manufacturing services. The portfolio is organized around two primary expression platforms—Microbial CDMO Services and Mammalian CDMO Services—supplemented by CMC Services, CDMO Support Services, and proprietary technology. Microbial services leverage E.coli and yeast systems via the proprietary Keystone™ Expression System, while mammalian services utilize CHO cell platforms including the ThermoFisher Freedom™ CHO-S system. The integrated offering spans the full product lifecycle from DNA to IND submission through commercial manufacturing, with capabilities including strain/cell line development, process development, analytical development, cGMP manufacturing, regulatory support, and global logistics. Recent additions include in-house cell line development (June 2026) and formulation development (September 2025) that complete the end-to-end service continuum.
Differentiator
Problem solved
Functional benefit
Products and services
- Microbial CDMO Services End-to-end microbial-derived biologics development and manufacturing services, including strain development using E. coli and yeast (Pichia pastoris, Saccharomyces cerevisiae), process development, analytical development, and cGMP manufacturing with up to 1,000L capacity. Targeted at biotech and pharma clients developing microbial-expressed proteins, enzymes, and other biologics.
- Mammalian CDMO Services Mammalian cell culture services from cell line development to commercial manufacturing of monoclonal antibodies, fusion proteins, bispecifics, TriKEs, cytokines, and enzymes using CHO cells with up to 2,000L single-use bioreactor capacity. Targeted at developers of complex mammalian-expressed biologics.
- CMC Services Chemistry, Manufacturing, and Controls services including regulatory affairs guidance, process characterization using Quality by Design (QbD) approaches, and process validation supporting product commercialization. Targeted at biologic developers seeking CMC and regulatory support across pre-IND through commercial phases.
- CDMO Support Services Comprehensive CDMO support services including global logistics, stability testing, and analytical and microbial testing for drug substance and drug product release. Targeted at biologics developers needing end-to-end release and distribution support.
- Fill-Finish Services Early-phase vial filling and labeling services for preclinical and Phase 1 drug products, supported by semi-automated pumps and a 1,200-batch vial filling capacity. Targeted at biotech clients preparing clinical trial material.
- Keystone Expression System Proprietary E. coli expression platform offering royalty-free control over the manufacturing process by simultaneously evaluating multiple strains in scaled-down batch and fed-batch formats, enabling high-productivity microbial production for biologic developers.
- In-House Cell Line Development Services Launched in June 2026, an in-house mammalian cell line development service that generates stable, high-producing CHO cell lines with headline titers reaching up to 10 g/L for monoclonal antibodies, providing an integrated path from DNA to IND submission for biologic developers.
- In-House Formulation Development Services Launched in September 2025, in-house formulation development services grounded in Quality by Design (QbD) principles, delivering speed, safety, and data-driven precision to biologic drug developers as part of Cytovance's end-to-end CDMO offering.
Quantifiable outcome
- 84 proteins successfully expressed in microbial systems over the past decade
- +5 more outcomes
Companies that use Cytovance Biologics
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Cytovance Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Cytovance Biologics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Anixa BiosciencescoreCytovance entered into a development and manufacturing agreement with Anixa Biosciences for the cGMP manufacture of clinical materials to support its planned Phase 2 clinical trial of its breast cancer vaccine. The vaccine, developed in collaboration with Cleveland Clinic, targets alpha-lactalbumin. Phase 1 results demonstrated safety, tolerability at maximum tolerated dose, and immune responses in 74% of participants. Cytovance's expertise in cGMP biologics production provides the technical strength and reliability necessary for the Phase 2 development.
- ExcellGene SAcoreCytovance partnered with ExcellGene SA to provide cutting-edge options for mammalian-expressed products. This partnership offers the industry integrated solutions for mammalian-expressed large molecule biologics, combining ExcellGene's expression platform expertise with Cytovance's manufacturing capabilities.
- CelltheoncoreCytovance partnered with Celltheon to offer a complete, U.S.-based platform solution for mAbs and difficult-to-express proteins. This partnership provides an integrated solution for customers seeking to outsource cell line development through to cGMP manufacturing, leveraging Celltheon's platform expertise with Cytovance's manufacturing capabilities.
- Vectron BiosolutionscoreCytovance partnered with Vectron Biosolutions for custom microbial strain development using Vectron's proprietary expression and secretion technologies. The partnership leverages Vectron's expertise in E. coli-based expression and secretion technologies to custom-engineer vectors for maximal titers of biologically active proteins, achieving secreted titers in the g/L scale. The collaboration utilizes Vectron's VB Secretion technology to direct transport of proteins out of the cell, preventing insoluble aggregate accumulation and enabling significant downstream purification resource reductions.
- AlcamicoreCytovance announced a strategic collaboration with Alcami Corporation to expand large molecule biologic manufacturing and sterile fill-finish offerings. The partnership combines Cytovance's bulk drug substance development and manufacturing services with Alcami's expertise in liquid and lyophilization sterile filling, packaging, labeling, formulation, release, and stability testing. This best-of-breed partnership expedites sterile injectables to patients through optimized transfer of bulk drug substance to finished drug product. The two companies are coordinating manufacturing processes and quality systems.
- PolyPeptideminorCytovance and PolyPeptide announced a collaboration to offer integrated peptide production for microbial and mammalian-expressed peptide drugs. This collaboration provides an integrated solution for customers seeking to outsource the development and manufacturing of peptide therapeutics.
- PhenotypecacoreCytovance partnered with Phenotypeca to enhance Saccharomyces cerevisiae strain development for microbial biomanufacturing. The partnership leverages Phenotypeca's proprietary QTL (Quantitative Trait Loci) technology, which integrates breeding methods with genomic-based screening to fine-tune yeast strains for specific proteins. This enables multi-parameter optimization for premium recombinant protein manufacturing processes, generating and screening billions of progeny strains to identify top performers.
Scale indicators11 records
Recent moves9 records
Expansion highlights4 records
Cytovance Biologics competitors and assessment
Company assessmentBroad incumbents
- FUJIFILM Diosynth Biotechnologies: Large-scale biologics CDMO with microbial and mammalian capabilities, including cGMP manufacturing and process development. Broad incumbent with overlapping service portfolio but significantly larger capacity and global footprint than Cytovance.
- Lonza: World's largest CDMO with comprehensive biologics (mammalian and microbial) and small molecule services across global mega-scale facilities. Comparable as a broad incumbent in biologics CDMO with overlapping expression platforms but vastly larger scale; Cytovance CCO held leadership roles at Lonza.
- Samsung Biologics: One of the world's largest contract biologics manufacturers with multi-10,000L bioreactor capacity serving global pharma and biotech. Broad incumbent offering overlapping mammalian CDMO services but at a dramatically larger scale than Cytovance.
- Boehringer Ingelheim BioXcellence: Global biologics CDMO operated by Boehringer Ingelheim, providing mammalian cell culture and microbial contract manufacturing at commercial scale. Broad incumbent with similar mammalian/microbial focus but vastly greater scale; Cytovance CCO and R&D Director previously held roles there.
Direct peers
- AGC Biologics: Global CDMO offering mammalian and microbial biologics development and manufacturing across multiple sites. Directly comparable as a mid-to-large biologics CDMO serving similar biotech and pharma clients with overlapping expression platforms; Cytovance CCO Axel Schleyer previously held leadership roles there.
- Stelis BioPharma: Bioprocess CDMO offering microbial, mammalian, and fill-finish services to global clients. Comparable as a mid-sized biologics CDMO with similar business model; Cytovance CCO Axel Schleyer was previously SVP of Business Development at Stelis.
- Northway Biotech: Contract development and manufacturing organization specializing in microbial and mammalian biologics. Comparable as a mid-sized biologics CDMO with similar expression platform breadth; Cytovance Sr. Director of Manufacturing Brent Van Rite previously held manufacturing leadership there.
- BioVectra: Canadian CDMO specializing in biologics (microbial fermentation and mammalian cell culture) and small molecule manufacturing. Comparable mid-sized CDMO with dual platform expression capabilities serving biotech and pharma clients.
- Alcami Corporation: U.S.-based CDMO providing biologics and small molecule manufacturing including sterile fill-finish. Directly comparable as a strategic partner and peer CDMO; Cytovance and Alcami have a formal collaboration combining bulk drug substance (Cytovance) with fill-finish (Alcami).
- Aragen Bioscience: Biologics CDMO and contract research services provider with mammalian and microbial capabilities. Directly comparable as a mid-sized CDMO with overlapping services; Cytovance CCO Axel Schleyer was previously President and CEO, and Sr. Director Brent Van Rite also held manufacturing roles there.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Cytovance Biologics social profiles
Digital presenceCytovance Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cytovance Biologics leadership team
Management profileNumber of profiles
Profiles7 records
Cytovance Biologics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cytovance Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cytovance Biologics
What does Cytovance Biologics do?
Cytovance Biologics is a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) that develops and manufactures large-molecule therapeutics—including monoclonal antibodies, fusion proteins, enzymes, vaccines, and recombinant proteins—from both mammalian cell culture (CHO) and microbial fermentation (E. coli and yeast). The company offers end-to-end services spanning strain and cell line development, upstream and downstream process development, analytical development, cGMP manufacturing (up to 2,000L single-use bioreactors and 1,000L microbial fermenters), fill-finish, regulatory support, and global logistics.
Is Cytovance Biologics a public or private company?
Cytovance Biologics is a private company. It is classified as private equity controlled and is currently operating.
When was Cytovance Biologics founded?
Cytovance Biologics was founded in 2005. It employs 251 to 500 people.
Where is Cytovance Biologics based?
Cytovance Biologics is headquartered in Oklahoma City, United States, in the North America region.
How does Cytovance Biologics make money?
Two revenue lines are on record. cGMP Contract Manufacturing (Clinical & Commercial) is the primary driver. The others are process Development and Analytical Services.
Who are Cytovance Biologics's main competitors?
Broad incumbents on record are FUJIFILM Diosynth Biotechnologies, Lonza, Samsung Biologics and Boehringer Ingelheim BioXcellence. Direct peers are AGC Biologics, Stelis BioPharma, Northway Biotech, BioVectra, Alcami Corporation and Aragen Bioscience.
Does Cytovance Biologics have an API?
No public API is recorded for Cytovance Biologics.
What industry is Cytovance Biologics in?
Cytovance Biologics's product category is Biologics Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 541714 and its SIC code is 8731.